• End date
    Dec 30, 2024
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 26 January 2021
liver cancer
hepatic arterial infusion
tumour thrombus


Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for treatments. Although BCLC (Barcelona clinical liver cancer) system recommend to palliative targeted treatment, the East Asian countries recommend to resection or transartery chemoembolization (TACE).

Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC.

Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.

Whether TACE-HAIC would improve survival for patients with PVTT is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.

Condition Adenocarcinoma, Malignant Adenoma, Adenocarcinoma, HEPATIC NEOPLASM, Liver Cancer, HEPATOCELLULAR CARCINOMA, Portal Vein Thrombosis, Liver Cancer, Malignant Adenoma, liver cell carcinoma
Treatment Surgery Alone, neo-TACE-HAIC+Surgery
Clinical Study IdentifierNCT04181931
SponsorSun Yat-sen University
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18-75 years
Patients with resectable primary hepatocellular carcinoma and portal vein tumor thrombus, which was not located in main portal vein
Child-Pugh A or B (7 score) liver function
With more than 3 months expected survival
The volume of residual liver more than 30%

Exclusion Criteria

Patients with primary hepatocellular carcinoma and major portal vein tumor thrombus
With extrahepatic metastasis or unresectable HCC
Pregnant woman or sucking period
With other malignant cancer
Received chemotherapy, target therapy or immunosuppressive drugs therapy before this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note